Genomes and Genes

Species

Massimo Negrini

Summary

Affiliation: University of Ferrara
Country: Italy

Publications

  1. Callegari E, Domenicali M, Shankaraiah R, D Abundo L, Guerriero P, Giannone F, et al. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids. 2018;14:239-250 pubmed publisher
    ..In summary, in this article, we not only report a simple model of liver cancer in a cirrhotic background but also provide evidence for a potential miRNA-based approach to reduce the risk of HCC development. ..
  2. Lupini L, Moretti A, Bassi C, Schirone A, Pedriali M, Querzoli P, et al. High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. Sci Rep. 2018;8:4371 pubmed publisher
    ..Because of its high sensitivity, the approach may potentially be applicable to patients with non-metastatic disease. ..
  3. Callegari E, D Abundo L, Guerriero P, Simioni C, Elamin B, Russo M, et al. miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Mol Ther Nucleic Acids. 2018;11:485-493 pubmed publisher
    ..Remarkably, the anti-tumor activity of miR-199a-3p mimics was comparable to that obtained with sorafenib. These results suggested that miR-199a-3p may be considered a promising HCC therapeutic option. ..
  4. Ferracin M, Salamon I, Lupini L, Miotto E, Sabbioni S, Negrini M. Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR. J Vis Exp. 2016;: pubmed publisher
    ..Here, we describe how performing this technique to assess miRNA amount in biological fluids, such as plasma and serum, is both feasible and effective. ..
  5. request reprint
    Negrini M, Gramantieri L, Sabbioni S, Croce C. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem. 2011;11:500-21 pubmed
    ..In this context, the liver represents an organ of election to test therapeutic possibilities associated with miRNAs. ..
  6. Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova Faltejskova P, et al. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer. 2015;15:808 pubmed publisher
  7. Shankaraiah R, Veronese A, Sabbioni S, Negrini M. Non-coding RNAs in the reprogramming of glucose metabolism in cancer. Cancer Lett. 2018;419:167-174 pubmed publisher
  8. Negrini M. Change of Title: Microarrays Becomes High-Throughput. High Throughput. 2017;6: pubmed publisher
    ..MDPI's journal Microarrays released its first volume in 2012. Since then, the journal has published 129 articles on the topic of microarrays, including their applications, analysis and new developments. [...]. ..
  9. Negrini M, Nicoloso M, Calin G. MicroRNAs and cancer--new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21:470-9 pubmed publisher
    ..New diagnostic classifiers based on miRNAs will soon be available for medical practitioners and, even more importantly, miRNAs may become novel anti-cancer tools. ..

More Information

Publications10

  1. Negrini M, Cutrona G, Bassi C, Fabris S, Zagatti B, Colombo M, et al. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin Cancer Res. 2014;20:4141-53 pubmed publisher
    ..Collectively, this information can be used for developing miRNA-based therapeutic strategies in CLL. ..